We have recently studied the impact of the growth factor receptor expression and the putative ovarian cancer stem cell marker CD44 on the sensitivity of a large panel of human ovarian cancer cells to treatment with various forms of HER-TKIs (Gefitinib, Erlotinib, Lapatinib, Sapitinib, Afatinib, Canertinib, Neratinib) and other TKIs including crizotinib (C-met/Alk inhibitor), NVP-AEW541 (IGF-1R inhibitor), dasatinib (v-abl/src/c-KIT TKI) and imatinib (v-abl/c-KIT/PDGFR TKI) [33]. This evidence concerns the gene SRC and ovarian cancer.